Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

By Sandeep T Patil, Lu Zhang, F. Martényi, S. Lowe, K. Jackson, B. Andreev, A. Avedisova, L. Bardenstein, I. Y. Gurovich, M. Morozova and 8 more. Nature Medicine, 2007

1,047 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/72d4270d6eadb66818908efa02fd6ab70b0358ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

In Molecular Biology

Citations in the corpus

NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons (2007, background): “and Moghaddam, 2007), and has been the basis for discovery of a novel antipsychotic drug (Moghaddam and Adams, 1998; Patil et al., 2007).”
Glutamate and dopamine in schizophrenia: an update for the 21st century (2015, positive): “It was found in an initial study to lead to significant improvements in positive and negative symptoms in patients with chronic schizophrenia (Patil et al., 2007).”
The dopamine hypothesis of schizophrenia: version III--the final common pathway. (2009, neutral): “A good example of such a new drug might be LY2140023, an mGlu 2/3 agonist.(171) If this were to be an effective antipsychotic and it could”
Metabotropic glutamate receptors: From the workbench to the bedside (2010, background): “…shown that the a 21-day treatment with LY2140023, the oral prodrug of the potent and selective mGlu2/3 receptor agonist, LY404039, was nearly as effective as treatment with the antipsychotic olanzapine in reducing both positive and negative symptoms in schizophrenic patients (Patil et al., 2007).”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders (2016, background): “Obstructive sleep apnoea (OSA) is a breathing disorder characterised by repeated collapse and obstruction of the upper airway, causing nocturnal hypoxia and sleep arousals (Patil et al., 2007a).”
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. (2008, background): “The importance of glutamatergic transmission in schizophrenia is underscored by the recent report that an mGlu2/3 agonist is effective, by itself, in treating the disease [49].”
Animal models of schizophrenia (2011, background): “Given the clinical propensity of existing antipsychotic drugs to reverse positive symptoms (Patil et al., 2007) and that isolation-induced locomotor hyperactivity results from mesolimbic dopamine hyperactivity, this behavioural test may be a useful model with high predictive validity to test drug…”